Manila Times Business
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
REYKJAVIK, Iceland, June 4, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the resubmission to the U.S. Food and Drug Administration (FDA) of Biologics License Applications (BLAs) for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab), and AVT06, a proposed biosimilar to Eylea® (aflibercept) 2 mg. Under a partnership with Teva Pharmaceutica
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Asset Workflows Appointed to NHS LPP Framework to Support Improved Asset Visibility and Utilisation Across the NHS
Just now
Realkredit Danmark A/S publishes new Base Prospectus for mortgage covered bonds and mortgage bonds
Just now
Sportradar Nets Official Wimbledon Tennis Data and AV Betting Rights Deal
Just now
Javier Bardem terrifies Amy Adams in TV adaptation of 'Cape Fear'
1h ago